Plasma proteomic signatures of preclinical Alzheimer's disease biomarkers and memory in clinically unimpaired older adults.

ABSTRACT:

Background

Multianalyte plasma proteomic panels that can accurately detect initial AD pathology in preclinical populations and simultaneously measure related biological processes relevant for disease risk are critical for advancing early detection and prognosis.

Methods

Using the NULISAseq CNS panel, we measured plasma from 193 clinically unimpaired (CU) older adults enrolled in the Stanford Aging and Memory Study (SAMS). We evaluated correspondence of core AD-relevant biomarkers Aβ42, Aβ40, pTau217, pTau181, GFAP, NfL, Aβ42/Aβ40, and pTau217/Aβ42 measured using NULISAseq and established Lumipulse immunoassays. ROC curve analyses compared the accuracy of these biomarkers for detecting Lumipulse CSF Aβ-positivity across platforms. Linear models were applied across 124 NULISAs

SUBMITTER: Trelle AN 

PROVIDER: S-EPMC12633621 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature